Immune therapy response prediction for esophageal cancer surgery
Part of Cancer, Digestive system clinical trials.
This trial is testing a way to predict whether immunotherapy (a treatment that helps your immune system fight cancer) will completely eliminate esophageal cancer before surgery. By examining lymph nodes, they hope to tailor treatment more personally.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with esophageal squamous cell carcinoma (a common type of esophageal cancer).
- You are healthy enough to have surgery to remove the cancer.
- You are scheduled to receive immunotherapy (a drug like PD-1 inhibitor) before your surgery.
- You are able to perform daily activities despite your cancer (ECOG score 0-2).
- You do not have active autoimmune diseases, uncontrolled heart problems, or certain infections like HIV, hepatitis B, or hepatitis C.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at whether certain cells in your lymph nodes (small immune glands) can predict how well PD-1 inhibitors (a type of immunotherapy) will work for your advanced or recurrent esophageal cancer. It aims to find a way to tailor treatment to each person.
This Phase 3 trial tests whether adding a PD-1 medicine (sintilimab) to standard chemo-radiation before surgery improves outcomes for locally advanced esophageal squamous cell cancer. It may help by strengthening the immune response while shrinking the tumor before an operation.
This study looks at patients with esophageal cancer who had a complete response to treatment given before surgery, meaning no cancer was found when the tumor was removed. It aims to understand their long-term outcomes and help guide future care.
This trial tests a combination of an immunotherapy drug (adebrelimab), an immune-boosting agent (thymalfasin), and standard chemotherapy given before surgery for esophageal cancer. The goal is to see if this combination can shrink the tumor and improve outcomes after surgery.
This study uses an “immune indicator model” to help predict how well a PD-1 antibody (a cancer-fighting immune drug) works when combined with chemotherapy for stage IV esophageal squamous cell cancer. If you qualify, you receive the treatment and the researchers also look for immune-related signs that may explain who benefits most.
This trial studies giving immunotherapy (anti–PD-1) together with chemotherapy before surgery for certain locally advanced esophageal squamous cell cancer. The goal is to improve how well the tumor responds before and after the operation.
Hear when a new Esophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.